243 related articles for article (PubMed ID: 23178755)
1. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
Mims A; Walker AR; Huang X; Sun J; Wang H; Santhanam R; Dorrance AM; Walker C; Hoellerbauer P; Tarighat SS; Chan KK; Klisovic RB; Perrotti D; Caligiuri MA; Byrd JC; Chen CS; James Lee L; Jacob S; Mrózek K; Bloomfield CD; Blum W; Garzon R; Schwind S; Marcucci G
Leukemia; 2013 Apr; 27(4):871-8. PubMed ID: 23178755
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
Huang X; Schwind S; Yu B; Santhanam R; Wang H; Hoellerbauer P; Mims A; Klisovic R; Walker AR; Chan KK; Blum W; Perrotti D; Byrd JC; Bloomfield CD; Caligiuri MA; Lee RJ; Garzon R; Muthusamy N; Lee LJ; Marcucci G
Clin Cancer Res; 2013 May; 19(9):2355-67. PubMed ID: 23493348
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of AR-42 and decitabine in acute myeloid leukemia.
Liva SG; Coss CC; Wang J; Blum W; Klisovic R; Bhatnagar B; Walsh K; Geyer S; Zhao Q; Garzon R; Marcucci G; Phelps MA; Walker AR
Leuk Lymphoma; 2020 Jun; 61(6):1484-1492. PubMed ID: 32037935
[TBL] [Abstract][Full Text] [Related]
4. The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.
Tarighat SS; Santhanam R; Frankhouser D; Radomska HS; Lai H; Anghelina M; Wang H; Huang X; Alinari L; Walker A; Caligiuri MA; Croce CM; Li L; Garzon R; Li C; Baiocchi RA; Marcucci G
Leukemia; 2016 Apr; 30(4):789-99. PubMed ID: 26536822
[TBL] [Abstract][Full Text] [Related]
5. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
Ranganathan P; Yu X; Santhanam R; Hofstetter J; Walker A; Walsh K; Bhatnagar B; Klisovic R; Vasu S; Phelps MA; Devine S; Shacham S; Kauffman M; Marcucci G; Blum W; Garzon R
Blood; 2015 Apr; 125(17):2689-92. PubMed ID: 25716206
[TBL] [Abstract][Full Text] [Related]
6. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Issa JP; Garcia-Manero G; Huang X; Cortes J; Ravandi F; Jabbour E; Borthakur G; Brandt M; Pierce S; Kantarjian HM
Cancer; 2015 Feb; 121(4):556-61. PubMed ID: 25336333
[TBL] [Abstract][Full Text] [Related]
7. Abnormal regulation of miR-29b-ID1 signaling is involved in the process of decitabine resistance in leukemia cells.
Ma J; Wen X; Xu Z; Xia P; Jin Y; Lin J; Qian J
Cell Cycle; 2023 May; 22(10):1215-1231. PubMed ID: 37032592
[TBL] [Abstract][Full Text] [Related]
8. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
[TBL] [Abstract][Full Text] [Related]
9. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
[TBL] [Abstract][Full Text] [Related]
10. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
Blum W; Schwind S; Tarighat SS; Geyer S; Eisfeld AK; Whitman S; Walker A; Klisovic R; Byrd JC; Santhanam R; Wang H; Curfman JP; Devine SM; Jacob S; Garr C; Kefauver C; Perrotti D; Chan KK; Bloomfield CD; Caligiuri MA; Grever MR; Garzon R; Marcucci G
Blood; 2012 Jun; 119(25):6025-31. PubMed ID: 22566605
[TBL] [Abstract][Full Text] [Related]
12. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
Blum W; Garzon R; Klisovic RB; Schwind S; Walker A; Geyer S; Liu S; Havelange V; Becker H; Schaaf L; Mickle J; Devine H; Kefauver C; Devine SM; Chan KK; Heerema NA; Bloomfield CD; Grever MR; Byrd JC; Villalona-Calero M; Croce CM; Marcucci G
Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7473-8. PubMed ID: 20368434
[TBL] [Abstract][Full Text] [Related]
13. Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.
Leonard SM; Perry T; Woodman CB; Kearns P
PLoS One; 2014; 9(1):e87475. PubMed ID: 24489920
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.
Xu X; Xie C; Edwards H; Zhou H; Buck SA; Ge Y
PLoS One; 2011 Feb; 6(2):e17138. PubMed ID: 21359182
[TBL] [Abstract][Full Text] [Related]
15. HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
Lai TH; Ewald B; Zecevic A; Liu C; Sulda M; Papaioannou D; Garzon R; Blachly JS; Plunkett W; Sampath D
Clin Cancer Res; 2016 Jul; 22(14):3537-49. PubMed ID: 26858310
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.
Garzon R; Liu S; Fabbri M; Liu Z; Heaphy CE; Callegari E; Schwind S; Pang J; Yu J; Muthusamy N; Havelange V; Volinia S; Blum W; Rush LJ; Perrotti D; Andreeff M; Bloomfield CD; Byrd JC; Chan K; Wu LC; Croce CM; Marcucci G
Blood; 2009 Jun; 113(25):6411-8. PubMed ID: 19211935
[TBL] [Abstract][Full Text] [Related]
17. Decitabine enhances targeting of AML cells by CD34
Cany J; Roeven MWH; Hoogstad-van Evert JS; Hobo W; Maas F; Franco Fernandez R; Blijlevens NMA; van der Velden WJ; Huls G; Jansen JH; Schaap NPM; Dolstra H
Blood; 2018 Jan; 131(2):202-214. PubMed ID: 29138222
[TBL] [Abstract][Full Text] [Related]
18. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
19. A novel epigenetic drug conjugating flavonoid and HDAC inhibitor confer suppression of acute myeloid leukemogenesis.
Zhang J; Gao X; Wei M; Li Y; Yang G; Yang C; Yu L
Clin Sci (Lond); 2021 Jul; 135(14):1751-1765. PubMed ID: 34282832
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
